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Introduction: Hematopoietic stem cell transplantation is a procedure now well established, although optimal outcomes
are not always achieved. Nowadays, mobilized peripheral CD34+ cells are the preferred source of hematopoietic stem
and progenitor cells for transplantation purposes. Unfortunately, very little is known about the peripheral CD34+ cells
composition in terms of committed myeloid progenitors and stem cells. In the present study, we intend to investigate the
proportions of hematopoietic progenitors and stem cells available in mobilized peripheral blood (PB) and correlate this
with clinical information and outcomes of patients who underwent a transplantation procedure. 
Materials (or patients) and methods: Multicolor flow-cytometry was used to analyze CD34+ cells from 4 bone marrow
(BM) samples and 9 PB samples from healthy volunteers and 32 mobilized PB samples from hematological patients prior
CD34+ cell harvesting. 
Results: RESULTS: Common myeloid progenitors (CMP) were present in a higher percentage in PB compared to BM
(47.8% ± 9.5 versus 27.6% ± 9.5 of CD34+ cells) while granulocyte-macrophage progenitors (GMP) were lower in PB
compared to BM (10.3% ± 6.9 versus 23.8% ± 7.2). No significant differences were noticed between PB and BM
hematopoietic stem cells (HSC). According to literature, progenitor fractions were equally distributed in BM (27.6% ± 9.5
CMP, 23.8% ± 7.2 GMP and 27.6% ± 16.2 megakaryocyte-erythroid progenitors, MEP). No differences in subpopulations
fractions were shown between baseline and mobilized CD34+ cells. Concerning the two samples mobilized with the
CXCR4 inhibitor Plerixafor instead of G-CSF only, we noticed that a more elevated ratio of GMP were released in PB:
37.8% in patient#1 and 33.8% in patient#2 compared to the average 16.31% of “G-CSF only” mobilized samples.
Analyzing CXCR4 levels among subpopulations of both mobilized or unmobilized samples, it was more expressed on
GMP than on the other CD34+ cell subsets.
A strong correlation was observed between the number of peripheral CD34+ cells and the number of circulating CMP
whose proportion did not change with increasing CD34+ cell release. White blood cells (WBC) count exhibited a
significant correlation with the number of mobilized HSC; on the contrary, WBC, hemoglobin and platelet levels did not
show correlations with the number of mobilized CMP/GMP/MEP.
We then looked at possible relationships between the number of re-infused subpopulations and the hematological
recovery after an auto-transplantation conditioned by high dose chemotherapy. A tendency to inverse correlation was
shown between the number of re-infused progenitors and the days of aplasia, as well as between the number of re-
infused MEP and erythrocyte/platelet transfusions. However, these results did not reach a statistical significance,
probably for the too low patient number.
Conclusion: CD34+ cell subset composition shows differences between BM and PB. We do not know yet if variabilities in
the proportions of different progenitor/stem cell re-infused can influence clinical issues such as infections complications
and transfusion requirement in patient undergoing an hematopoietic stem cell transplantation. A deep understanding of
these mechanisms may guide the clinician in the choice of the most suitable chemotherapy or mobilizing regimen and
lead up to an improved clinical outcomes of such patients. 
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